Mostrar el registro sencillo del ítem
Artículo
First Steps Towards a Vaccine against Acinetobacter baumannii
dc.creator | García Quintanilla, Meritxell de Jesús | es |
dc.creator | Pulido, Marina R. | es |
dc.creator | McConnell, Michael J. | es |
dc.date.accessioned | 2024-06-28T09:25:02Z | |
dc.date.available | 2024-06-28T09:25:02Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | García Quintanilla, M.d.J., Pulido, M.R. y McConnell, M.J. (2013). First Steps Towards a Vaccine against Acinetobacter baumannii. Current Pharmaceutical Biotechnology, 14 (10), 897-902. https://doi.org/10.2174/1389201014666131226123511. | |
dc.identifier.issn | 1389-2010 | es |
dc.identifier.issn | 1873-4316 | es |
dc.identifier.uri | https://hdl.handle.net/11441/160958 | |
dc.description.abstract | Acinetobacter baumannii has become an important cause of human infections, most notably in the hospital setting. In addition, the global dissemination of multidrug resistant strains has complicated effective antibiotic therapy of infections produced by this pathogen, necessitating the development of novel treatment and prevention strategies. Active and passive immunization approaches have begun to be explored in experimental animal models as potential alternative therapies for A. baumannii. In the present review, we discuss the advantages and disadvantages of each therapeutic strategy with respect to A. baumannii infections, and summarize the recent studies that have explored these approaches. The single antigen candidates that have been tested include, the outer membrane protein OmpA, the membrane transporter Ata, the biofilm-associated protein Bap, the K1 capsular polysaccharide and the membrane associated polysaccharide poly-N-acetyl-β -(1-6)-glucosamine. Strategies employing multicomponent antigens include inactivated whole cells, outer membrane complexes and outer membrane vesicles. The strengths and limitations of each approach are discussed and the challenges that remain to be addressed for successful A. baumannii vaccine development are highlighted. | es |
dc.description.sponsorship | European Community\'s 7 th Programme Framework (MagicBullet) 278232 | es |
dc.description.sponsorship | European's Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases REIPI RD06/0008/0000 | es |
dc.description.sponsorship | European\'s Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases REIPI RD06/0008/0000 | es |
dc.description.sponsorship | Ministerio de Econom a y Competitividad of Spain CP11/00314 | es |
dc.description.sponsorship | Ministerio de Econom a y Competitividad, Instituto de Salud Carlos III | es |
dc.format | application/pdf | es |
dc.format.extent | 6 | es |
dc.language.iso | eng | es |
dc.publisher | Bentham Science | es |
dc.relation.ispartof | Current Pharmaceutical Biotechnology, 14 (10), 897-902. | |
dc.subject | Acinetobacter baumannii | es |
dc.subject | Vaccine | es |
dc.subject | Passive immunization. | es |
dc.title | First Steps Towards a Vaccine against Acinetobacter baumannii | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/acceptedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Microbiología | es |
dc.date.embargoEndDate | 2014 | |
dc.relation.publisherversion | https://www.eurekaselect.com/article/58291 | es |
dc.identifier.doi | 10.2174/1389201014666131226123511 | es |
dc.contributor.group | Universidad de Sevilla. CTS210: Resistencia a Antimicrobianos | es |
dc.journaltitle | Current Pharmaceutical Biotechnology | es |
dc.publication.volumen | 14 | es |
dc.publication.issue | 10 | es |
dc.publication.initialPage | 897 | es |
dc.publication.endPage | 902 | es |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
First steps towards a vaccine ... | 462.2Kb | [PDF] | Ver/ | |
Este registro aparece en las siguientes colecciones
Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.